<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03772249</url>
  </required_header>
  <id_info>
    <org_study_id>DCR-HBVS-101</org_study_id>
    <secondary_id>U1111-1220-7021</secondary_id>
    <nct_id>NCT03772249</nct_id>
  </id_info>
  <brief_title>Study of Safety and Tolerability of DCR HBVS</brief_title>
  <official_title>A Three-Part, Phase 1, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of DCR-HBVS in Healthy Volunteers and Patients With Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dicerna Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dicerna Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      DCR-HBVS will be evaluated for safety and efficacy in healthy volunteers and chronic
      hepatitis B patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DCR HBVS is being developed for the treatment of chronic hepatitis B (CHB) in adults. The
      study will be conducted in 3 parts, a single ascending-dose (SAD) phase in healthy volunteers
      (Group A), a single-dose (SD) phase in patients with CHB (Group B), and a multiple
      ascending-dose (MAD) phase in patients with CHB (Group C).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 28, 2018</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Progression from the SAD phase to the first cohort in the MAD phase is contingent upon the Safety Review Committee (SRC) review of a minimum of 14 days post-dose safety and tolerability data from all HV in at least the first 2 SAD cohorts. The SRC will select one (or more) well-tolerated dose(s) from the SAD phase for administration in the SD and MAD phases. In all study phases, dosing will be staggered with the use of sentinel participants to allow time for the assessment of safety before additional subjects are exposed to study drug.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>This is a double-blind placebo-controlled study in which the study site team, the Sponsor, and the participants will be blinded to treatment assignment. The unblinded pharmacist will cover each syringe, prior to transport to the bedside, to ensure blinding. Participants will be centrally assigned to randomized study intervention using an Interactive Voice/Web Response System (IVRS/IWRS).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of healthy volunteers with Adverse Events as assessed by CTCAE v5.0</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number of participants with abnormalities in vital signs, electrocardiogram (ECG), and clinically significant laboratory findings</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number participants with non-cirrhotic chronic Hepatitis B with Adverse Events as assessed by CTCAE v5.0</measure>
    <time_frame>16 weeks</time_frame>
    <description>Number of participants with abnormalities in vital signs, electrocardiogram (ECG), and clinically significant laboratory findings</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetics of DCR-HBVS in healthy volunteers by monitoring plasma pharmacokinetics profiles of DCR-S219</measure>
    <time_frame>4 weeks</time_frame>
    <description>Measure the amount of DCR-HBVS excreted in urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetics of DCR-HBVS in healthy volunteers by monitoring through concentrations of DCR-S219</measure>
    <time_frame>4 weeks</time_frame>
    <description>Measure the amount of DCR-HBVS renal clearance (CLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetics of DCR-HBVS in participants with non-cirrhotic CHB by monitoring plasma pharmacokinetics profiles of DCR-HBVS.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measure the amount of DCR-HBVS excreted in urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetics of DCR-HBVS in participants with non-cirrhotic CHB by monitoring through concentrations of DCR-HBVS.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measure DCR-HBVS renal clearance (CLR).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To evaluate the preliminary antiviral efficacy of DCR-HBVS in participants with CHB by monitoring changes in serum HBsAg levels (all Group B and C participants)during and after single dose and 12 weeks of treatment with DCR HBVS.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Proportion of participants achieving at least a 1-log reduction in HBsAg AND achieving a HBsAg level &lt; 100 IU/mL at last scheduled visit Time to HBsAg loss (Kaplan-Mayer) Time to anti-HBs seroconversion</description>
  </other_outcome>
  <other_outcome>
    <measure>To evaluate the preliminary antiviral efficacy of DCR-HBVS in participants with CHB by monitoring HBeAg levels (HBeAg+ participants only) during and after single dose and 12 weeks of treatment with DCR HBVS.</measure>
    <time_frame>12 weeks</time_frame>
    <description>% of participants with HBeAg loss and anti HBe at last scheduled visit (if HBeAg positive at study entry)</description>
  </other_outcome>
  <other_outcome>
    <measure>To evaluate the preliminary antiviral efficacy of DCR-HBVS in participants with CHB by monitoring HBV DNA levels (all Group B and C participants) during and after single dose and 12 weeks of treatment with DCR HBVS.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Proportion of participants achieving HBV DNA &lt; 2000 IU/mL (if &gt; 2,000 IU/mL at Baseline); and proportion of participants achieving PCR-nondetectable HBV DNA (if HBV DNA was detectable at Baseline).</description>
  </other_outcome>
  <other_outcome>
    <measure>To characterize the pharmacodynamics (PD) of DCR-HBVS on plasma levels of HBsAg and HBV in blood.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Track post-treatment duration of any observed efficacy effects.</description>
  </other_outcome>
  <number_of_arms>18</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Cohort A1 DCR-HBVS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, Subcutaneous injection of 0.1mg/kg of DCR-HBVS (HV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A1 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose, Subcutaneous injection of 0.1mg/kg of Placebo for DCR-HBVS (HV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A2 DCR-HBVS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, Subcutaneous injection of 1.5mg/kg of DCR-HBVS (HV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A2 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose, Subcutaneous injection of 1.5mg/kg of Placebo for DCR-HBVS (HV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A3 DCR-HBVS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, Subcutaneous injection of 3mg/kg of DCR-HBVS (HV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A3 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose, Subcutaneous injection of 3mg/kg of Placebo for DCR-HBVS (HV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A4 DCR-HBVS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, Subcutaneous injection of 6mg/kg of DCR-HBVS (HV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A4 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose, Subcutaneous injection of 6mg/kg of Placebo for DCR-HBVS (HV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A5 DCR-HBVS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, Subcutaneous injection of 12mg/kg of DCR-HBVS (HV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A5 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose, Subcutaneous injection of 12mg/kg of Placebo for DCR-HBVS (HV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B DCR-HBVS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, Subcutaneous injection of 3mg/kg of for DCR-HBVS (NUC naïve, CHB)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose, Subcutaneous injection of 3mg/kg of Placebo for DCR-HBVS (NUC naïve, CHB)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C1 DCR-HBVS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 doses- Subcutaneous injection of 1.5mg/kg of DCR-HBVS administered every 28 days (NUC experienced, CHB)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C1 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 doses- Subcutaneous injection of 1.5mg/kg of Placebo for DCR-HBVS administered every 28 days (NUC experienced, CHB)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C2 DCR-HBVS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 doses- Subcutaneous injection of 3mg/kg of DCR-HBVS administered every 28 days (NUC experienced, CHB)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C2 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 doses- Subcutaneous injection of 3mg/kg of Placebo for DCR-HBVS administered every 28 days (NUC experienced, CHB)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C3 DCR-HBVS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 doses- Subcutaneous injection of 6mg/kg of DCR-HBVS administered every 28 days (NUC experienced, CHB)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C3 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 doses- Subcutaneous injection of 6mg/kg of Placebo for DCR-HBVS administered every 28 days (NUC experienced, CHB)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DCR-HBVS</intervention_name>
    <description>DCR-HBVS is a synthetic ribonucleic acid interference (RNAi) drug that consists of a double-stranded oligonucleotide conjugated to N-acetyl-D-galactosamine (GalNAc) ligands. DCR-HBVS is a sterile solution of the siRNA (DCR-S219) at a concentration of 195 mg/mL in water for injection (WFI).</description>
    <arm_group_label>Cohort A1 DCR-HBVS</arm_group_label>
    <arm_group_label>Cohort A2 DCR-HBVS</arm_group_label>
    <arm_group_label>Cohort A3 DCR-HBVS</arm_group_label>
    <arm_group_label>Cohort A4 DCR-HBVS</arm_group_label>
    <arm_group_label>Cohort A5 DCR-HBVS</arm_group_label>
    <arm_group_label>Cohort B DCR-HBVS</arm_group_label>
    <arm_group_label>Cohort C1 DCR-HBVS</arm_group_label>
    <arm_group_label>Cohort C2 DCR-HBVS</arm_group_label>
    <arm_group_label>Cohort C3 DCR-HBVS</arm_group_label>
    <other_name>DCR-S219</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for DCR-HBVS</intervention_name>
    <description>Sterile 9% saline for injection.</description>
    <arm_group_label>Cohort A1 Placebo</arm_group_label>
    <arm_group_label>Cohort A2 Placebo</arm_group_label>
    <arm_group_label>Cohort A3 Placebo</arm_group_label>
    <arm_group_label>Cohort A4 Placebo</arm_group_label>
    <arm_group_label>Cohort A5 Placebo</arm_group_label>
    <arm_group_label>Cohort B Placebo</arm_group_label>
    <arm_group_label>Cohort C1 Placebo</arm_group_label>
    <arm_group_label>Cohort C2 Placebo</arm_group_label>
    <arm_group_label>Cohort C3 Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy at the time of screening as determined by medical evaluation.

          -  Capable of giving informed consent.

          -  12-lead ECG within normal limits or with no clinically significant abnormalities.

          -  Negative screen for alcohol or drugs of abuse.

          -  Non-smokers for at least 3 months with a negative urinary cotinine concentration at
             screening.

          -  BMI within range 18.0 - 32.0 kg/m2 (inclusive).

          -  Female participants not pregnant, not breastfeeding, and not of childbearing potential
             or willing to follow contraceptive guidance.

          -  Chronic hepatitis B infection (Group B and C only).

          -  Clinical history compatible with compensated liver disease with no evidence of
             cirrhosis (Group B and C only).

          -  Continuously on nucleotides (NUC) therapy for at least 12 weeks prior to screening
             (Group C only).

        Exclusion Criteria:

          -  History of any medical condition that may interfere with the absorption, distribution,
             or elimination of study drug.

          -  Poorly controlled or unstable hypertension.

          -  History of diabetes mellitus treated with insulin or hypoglycemic agents.

          -  History of asthma requiring hospital admission within the preceding 12 months.

          -  Evidence of G-6-PD deficiency.

          -  Currently poorly controlled endocrine conditions, excluding thyroid conditions.

          -  History of multiple drug allergies or history of allergic reaction to an
             oligonucleotide or GalNAc.

          -  Clinically relevant surgical history.

          -  Use of prescription medications (excluding contraception for women) within 4 weeks
             prior to the administration of study intervention.

          -  Use of clinically relevant over-the-counter medication or supplements (excluding
             routine vitamins) within 7 days of first dosing.

          -  Has received an investigational agent within the 3 months prior to dosing or is in
             follow-up of another study.

          -  Antiviral therapy (other than entecavir or tenofovir) within 3 months of screening or
             treatment with interferon in the last 3 years (Group B and C only).

          -  Use within the last 6 months of anticoagulants or systemically administered
             corticosteroids, immunomodulators, or immunosuppressants (Group B and C only).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralf Rosskamp, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dicerna Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>VP, Clinical Development</last_name>
    <phone>617-612-6260</phone>
    <email>mcioffi@dicerna.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Monash Health</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vilma Vasquez-Ferriggi</last_name>
      <phone>8572 2573</phone>
    </contact>
    <contact_backup>
      <last_name>Trish Anderson</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Melbourne</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacinta McMahon</last_name>
      <phone>+61 3 9231 3518</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital (The University of Hong Kong)</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin-Hee Kim</last_name>
      <phone>821085753178</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul Metropolitan Government - Seoul National University Boramae Medical Center</name>
      <address>
        <city>Soeul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hye-Lim Hwang</last_name>
      <phone>8228702861</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Middlemore Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>King Culalongkorn Memorial Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sirintip Piyarad</last_name>
      <phone>6622564482</phone>
      <phone_ext>4725</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital</name>
      <address>
        <city>Khon Kaen</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pimumporn Tungtrakul</last_name>
      <phone>6643366558</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 3, 2018</study_first_submitted>
  <study_first_submitted_qc>December 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2018</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Hepatitis B</keyword>
  <keyword>DNA Virus Infections</keyword>
  <keyword>CHB</keyword>
  <keyword>HBsAg</keyword>
  <keyword>Liver Disease</keyword>
  <keyword>RNAi</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

